Physician profile
Danielle A Poth
NPI 1851024244
$8,979.16
in general payments reported to CMS, 2019-2025
26 companies · $5,470 in 2025
The $5,470 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $742 · 2024: $2,767 · 2025: $5,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,924 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,924.17 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,657.41 | 2023-2025 | Otezla, Otezla, Enbrel |
| Ucb, INC. | $1,369.73 | 2023-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $1,108.26 | 2023-2025 | |
| Janssen Biotech, INC. | $1,003.71 | 2024-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $678.99 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $442.40 | 2023-2025 | Saphnelo |
| Lilly USA, LLC | $439.37 | 2023-2025 | Olumiant, Taltz, Zepbound |
| Glaxosmithkline, LLC. | $417.95 | 2023-2025 | Benlysta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $384.80 | 2023-2025 | Ofev, Spevigo, Cyltezo |
| Genzyme Corporation | $242.40 | 2024-2025 | |
| Genentech USA, INC. | $241.34 | 2024-2025 | Actemra, Gazyva |
| Aurinia Pharma U.S., INC. | $199.49 | 2024-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $174.54 | 2025 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $163.93 | 2024-2025 | Orencia |
| Pfizer INC. | $91.86 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $62.99 | 2024 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $57.88 | 2023 | Ultomiris |
| Bioventus LLC | $36.29 | 2024 | Supartz Fx Sodium Hyaluronate, Durolane |
| Almatica Pharma LLC | $35.96 | 2025 | Teriparatide, Loreev Xr |
| Scilex Pharmaceuticals INC. | $35.61 | 2024-2025 | |
| Fidia Pharma USA INC. | $29.59 | 2023 | Triluron, Hymovis |
| Actelion Pharmaceuticals US, INC. | $24.72 | 2025 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals, Ltd. | $23.86 | 2023 | Arcalyst |
| Tonix Medicines, INC. | $22.53 | 2025 | Tonmya |
| Elevate Surgical Co | $16.88 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $16.67 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Poth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.